After Moderna announced business and clinical updates across its franchises at the company’s annual R&D, Jefferies said the company reported “nice,” positive flu data and affirmed a “combo” update in Q4, but the “market seems only focused on Covid” and the Street seems “skeptical overall on jabs.” While admitting to needing to get through 2023 winter shots and 2024 to see if Moderna is going to get the revenues of $6B-$8B annually to support the $6B-$8B opex each year, the firm says “one might argue $15B cash + $15B Covid EV = $30B,” which means investors are “not paying much for pipeline now at $40B cap today.” Jefferies has a Buy rating and $175 price target on Moderna shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on MRNA:
- Moderna (NASDAQ:MRNA) Surges after Landing EU Approval
- Moderna sees combo flu/COVID vaccine available as early as 2025
- Moderna up after forecasting up to $15B in sales by 2027 from respiratory drugs
- Moderna price target lowered to $140 from $160 at Argus
- Early notable gainers among liquid option names on September 13th